| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.06.07 | Millennium Introduces New Oncology Molecule with Activity in Broad Range of Cancer Models | 33 | PR Newswire | CHICAGO, June 3 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today presented results of research on a new oncology molecule, MLN4924, a first-in-class, small molecule inhibitor of the... ► Artikel lesen | |
| 03.06.07 | Disney's 'Pirates' Continues to Ride Tidal Wave of Success at Global BoxOffice with Sensational Gross of US$625.3 Million | 22 | PR Newswire | BURBANK, California, June 3 /PRNewswire/ --
- Second Weekend Worldwide Gross Tops US$148 Million
Disney's swashbuckling blockbuster, "Pirates of the Caribbean: At World's
End," from... ► Artikel lesen | |
| 03.06.07 | Disney's 'Pirates' Continues to Ride Tidal Wave of Success at Global Box Office with Sensational Gross of $625.3 Million | 33 | PR Newswire | BURBANK, Calif., June 3 /PRNewswire-FirstCall/ -- Disney's swashbuckling blockbuster, "Pirates of the Caribbean: At World's End," from producer Jerry Bruckheimer and director Gore Verbinski, continued... ► Artikel lesen | |
| 03.06.07 | Herceptin(R) Used Pre-Operatively Can Eradicate the Tumour in Nearly Twice as Many Patients as Chemotherapy Alone | 30 | PR Newswire | CHICAGO, Illinois, June 3 /PRNewswire/ --
- Substantial Shrinkage of Cancer Tissue Increases Rate of Breast
Conserving Surgery in Patients With Advanced HER2-Positive Disease
- FOR... ► Artikel lesen | |
| 03.06.07 | VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients | 58 | PR Newswire | CHICAGO, June 3 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today reported on results presented by the University of Arkansas for Medical Sciences and the Center for Cancer Research... ► Artikel lesen | |
| 03.06.07 | Genomic Health, Inc. Announces Positive Results from First Study Using Oncotype DX in Node-Positive Breast Cancer Patients | 29 | PR Newswire | CHICAGO, June 3 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced positive results of a first study analyzing patient samples from a large trial conducted by the Eastern Cooperative Oncology... ► Artikel lesen | |
| 03.06.07 | VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients | 37 | PR Newswire | CHICAGO, June 3 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced positive data from clinical trials of VELCADE in newly diagnosed non-Hodgkin's lymphoma (NHL) patients at... ► Artikel lesen | |
| 03.06.07 | CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer | 41 | PR Newswire | CHICAGO, June 3 /PRNewswire/ -- Schering-Plough Corp. announced results from a Phase III study that showed maintenance chemotherapy with CAELYX(R) (pegylated liposomal doxorubicin hydrochloride) significantly... ► Artikel lesen | |
| 03.06.07 | QIAGEN and Digene Announce Merger Creating Market and Technology Leader In Molecular Diagnostics | 25 | PR Newswire | VENLO, Netherlands and GAITHERSBURG, Md., June 3 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) and Digene Corp. announced today a definitive agreement to combine... ► Artikel lesen | |
| 03.06.07 | Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer | 22 | PR Newswire | CHICAGO, June 3 /PRNewswire-FirstCall/ -- Today, Bristol-Myers Squibb reported results from a large randomized Phase III study of the investigational compound ixabepilone in patients with breast cancer... ► Artikel lesen | |
| 03.06.07 | GLAXOSMITHKLINE REPORTS POSITIVE NEW DATA ON TYKERB(R)(LAPATINIB) AT THE 2007 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING | 26 | PR Newswire | CHICAGO, June 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced positive data from three key studies on its first-in-class, oral small molecule HER2 kinase inhibitor, TYKERB(R) (lapatinib).... ► Artikel lesen | |
| 03.06.07 | FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer | 87 | PR Newswire | CHICAGO, June 3 /PRNewswire-FirstCall/ -- FOLFOX4, an Eloxatin(R) (oxaliplatin injection)-based chemotherapy regimen, significantly improved the overall survival (OS) of patients with surgically resected... ► Artikel lesen | |
| 03.06.07 | Millennium Advances Aurora A Kinase Program | 21 | PR Newswire | CHICAGO, June 3 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced two important advancements in its Aurora A kinase program. Preliminary results from a Phase I study of MLN8054... ► Artikel lesen | |
| 03.06.07 | Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer | 25 | PR Newswire | VANCOUVER, BC and CARLSBAD, CA, June 3 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. today announced encouraging preliminary data from a Phase I/II clinical... ► Artikel lesen | |
| 03.06.07 | Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer | 230 | PR Newswire | CHICAGO, June 3 /PRNewswire-FirstCall/ -- Oxford BioMedica and sanofi-aventis (EURONEXT: SAN) today announce new data from two Phase II trials of TroVax(R) in renal cancer. TroVax(R) is Oxford BioMedica's... ► Artikel lesen | |
| 03.06.07 | Poniard Pharmaceuticals Announces Results of Picoplatin Phase 2 Trial That Confirm and Extend Survival Benefit in Small Cell Lung Cancer | 21 | PR Newswire | SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that new picoplatin results confirm and... ► Artikel lesen | |
| 03.06.07 | Tapestry Pharmaceuticals Presents Phase I Data on TPI 287 at the 43rd ASCO Annual Meeting | 18 | PR Newswire | BOULDER, Colo., June 3 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today presented data from two Phase I clinical trials of TPI 287, the Company's leading drug candidate, at the 43rd... ► Artikel lesen | |
| 03.06.07 | Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO | 24 | PR Newswire | CHICAGO, June 3 /PRNewswire-FirstCall/ -- Exelixis, Inc. reported integrated data from six Phase II clinical trials of XL999 in patients with non-small cell lung cancer (NSCLC), renal cell carcinoma... ► Artikel lesen | |
| 03.06.07 | Pharmacyclics Announces Positive Final Results of Phase 2 Trial of Xcytrin(R) Plus Radiosurgery for Brain Metastases With Occult Tumors Detected in 24% of Patients | 18 | PR Newswire | CHICAGO and SUNNYVALE, Calif., June 3 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced final results from an open-label multi-center Phase 2 clinical trial, which indicated that Xcytrin(R)... ► Artikel lesen | |
| 03.06.07 | 'My Child Matters' Program One-Year Report Shows Measurable Improvement in Cancer Care for Children in Developing and Newly Industrialized Countries | 89 | PR Newswire | CHICAGO, June 3 /PRNewswire-FirstCall/ -- According to a report released today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the My Child Matters program launched... ► Artikel lesen |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 333 |
| BAYER | 209 |
| BYD | 201 |
| NVIDIA | 187 |
| NEL | 176 |
| PLUG POWER | 170 |
| TESLA | 164 |
| SUPER MICRO COMPUTER | 162 |
| APPLE | 154 |
| TUI | 152 |
| DEUTSCHE BANK | 142 |
| RHEINMETALL | 129 |
| AMAZON | 124 |
| RWE | 115 |
| DEUTSCHE LUFTHANSA | 112 |
| MERCEDES-BENZ | 110 |
| BERKSHIRE HATHAWAY | 104 |
| PAYPAL | 99 |
| BIONTECH | 97 |
| COMMERZBANK | 97 |
| ALLIANZ | 95 |
| RENK GROUP | 94 |
| CUREVAC | 90 |
| MICROSOFT | 86 |
| AIXTRON SE | 82 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
